Leadless Pacemakers Market To Reach $1.62 Billion By 2033

Leadless Pacemakers Market Growth & Trendss 

The global leadless pacemakers market size is anticipated to reach USD 1.62 billion by 2033, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.56% from 2026 to 2033. This growth is attributed to technological advancements, rising prevalence of heart diseases, and a preference for minimally invasive procedures. Moreover, the growing aging population globally propels the demand for leadless pacemakers, as bradycardia is common in the geriatric population. According to the Cleveland Clinic, approximately half a million of the geriatric population show the symptoms of bradycardia, thereby driving the industry.

Wireless or leadless pacemakers, frequently used in adult patients, have emerged as a potentially safe and efficient temporary alternative for children experiencing bradycardia, as revealed by research featured in Circulation: Arrhythmia and Electrophysiology, a peer-reviewed journal affiliated with the American Heart Association. This development is expected to be a potential driver for the market growth.

In addition, growing business initiatives by companies for leadless pacemakers propel the industry's growth. For instance, in January 2024, Medtronic plc announced it had received the CE (Conformite Europeenne) Mark for its Micra AV2 and Micra VR2, leadless pacemakers. The Micra AV2 and Micra VR2, which are recognized as the smallest pacemakers globally, offer extended battery life and simplified programming in comparison to earlier models of Micra pacemakers. Despite these advancements, they retain the numerous advantages of leadless pacing, including a reduction in complications when compared to traditional pacemakers.

 Request a free sample copy or view report summary: Leadless Pacemakers Market Report

Leadless Pacemakers Market Report Highlights

• By chambers, the single chamber segment accounted for the largest revenue share of 55.44% in 2025 due to technological advancements and the rising demand for minimally invasive cardiac devices.

• By brands, the Micra VR and VR2 segment accounted for the largest revenue share of 47.30% in 2025.

• By end use, the hospitals segment accounted for the largest revenue share of 89.08% in 2025.

• The North America leadless pacemakers industry dominated the market with a share of 69.56% in 2025, driven by technological innovation.

Leadless Pacemakers Market Segmentationn

Grand View Research has segmented the global leadless pacemakers market on the basis of chambers, brands, end use, and region:

Leadless Pacemakers Chambers Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)

• Single Chamber

• Dual Chamber

Leadless Pacemakers Brands Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)

• Micra VR and VR2

• Micra AV and AV2

• Abbott Aveir DR

• Abbott Aveir VR

• Abbott Aveir AR

Leadless Pacemakers End Use Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)

• Hospitals

• Outpatient Facilities

Leadless Pacemakers Regional Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Leadless Pacemakers Market

• Abbott

• Medtronic

• EBR Systems, Inc.

• Boston Scientific Corporation

• MicroPort Scientific Corporation